NCT06815497View on ClinicalTrials.gov

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

April 14, 2027

Study Completion Date

May 14, 2029

Conditions
Ovarian Cancer
Interventions
DRUG

Telmisartan

Telmisartan will be introduced as a 40 mg tablet to be taken orally once daily. In participants not experiencing telmisartan dose limiting toxicity, the dose will be escalated to a maximum of 80 mg

Trial Locations (1)

03756

Dartmouth Hitchcock, Lebanon

All Listed Sponsors
collaborator

Dartmouth-Hitchcock Medical Center

OTHER

lead

Tyler J Curiel

OTHER